حدد سهمًا أو عملة مشفرة في شريط البحث للحصول على ملخص
GRI Bio Inc.
GRIGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California. Address: 2223 Avenida de la Playa, LA Jolla, CA, United States, 92037
Analytics
سعر الهدف في وول ستريت
12 USDنسبة السعر إلى الأرباح
0.0135العائد الربحي
–السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
الشخصيات الرئيسية GRI
تحليلات الأرباح GRI
نمو الأرباح على مدى 5 سنوات
–النمو المستمر
–معدل الدفع 5 سنوات في المتوسط
–تاريخ الأرباح GRI
تقييم الأسهم GRI
المالية GRI
نتائج | 2019 | ديناميات |